Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024;14(s2):S257-S271.
doi: 10.3233/JPD-230411.

Defining Parkinson's Disease: Past and Future

Affiliations
Review

Defining Parkinson's Disease: Past and Future

Kristina Kulcsarova et al. J Parkinsons Dis. 2024.

Abstract

Parkinson's disease (PD) is the second most common still relentlessly progressive neurodegenerative disorder with a long period in which the pathophysiological process is already spreading but cardinal motor symptoms are not present. This review outlines the major developments and milestones in our understanding of PD that have shaped the way we define this disorder. Past criteria and definitions of PD have been based on clinical motor manifestations enabling diagnosis of the disease only in later symptomatic stages. Nevertheless, with advancing knowledge of disease pathophysiology and aim of early disease detection, a major shift of the diagnostic paradigm is being advocated towards a biological definition similar to other neurodegenerative disorders including Alzheimer's disease and Huntington's disease, with the ultimate goal of an earlier, disease course modifying therapy. We summarize the major pillars of this possible approach including in vivo detection of neuronal α-synuclein aggregation, neurodegeneration and genetics and outline their possible application in different contexts of use in the frame of biological PD definition.

Keywords: Parkinson’s disease; biomarkers; genetics; neurodegeneration; synuclein.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflict of interest to report.

Figures

Fig. 1
Fig. 1
Defining Parkinson’s disease – historical milestones, complexity of PD-related neurodegeneration and corresponding evolution of diagnostic criteria and definitions. PD, Parkinson’s disease; SN, substantia nigra, MPTP, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine; DBS, deep brain stimulation; SNCA, synuclein alpha gene; LB, Lewy bodies; α-syn, α-synuclein; SAA, seed amplification assays; GWAS, genome-wide association study; ANS, autonomic nervous system; ENS, enteric nervous system; GABA, gamma-aminobutyric acid; PIGD, postural instability and gait disturbance; UK, United Kingdom; MDS, International Parkinson and Movement Disorders Society; SynNeurGe, synuclein-neurodegeneration-genetics; NSD-ISS, neuronal α-synuclein disease integrated staging system. Created with BioRender.com.

References

    1. Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, Schrag A-E, Lang AE (2017) Parkinson disease. Nat Rev Dis Primer 3, 17013. - PubMed
    1. Przedborski S (2017) The two-century journey of Parkinson disease research. Nat Rev Neurosci 18, 251–259. - PubMed
    1. Li S, Le W (2017) Milestones of Parkinson’s disease research: 200 years of history and beyond. Neurosci Bull 33, 598–602. - PMC - PubMed
    1. Parkinson J (2002) An essay on the shaking palsy. J Neuropsychiatry Clin Neurosci 14, 223–236. - PubMed
    1. Charcot J-M(1825-1893) A du texte, Vulpian A (1826–1887)Adu texte (1862) De la paralysie agitante/par MM. J.-M. Charcot, A. Vulpian.

Substances

LinkOut - more resources